Role of cytokines and platelet-activating factor in inflammatory bowel disease: Implications for therapy

Diseases of the Colon and Rectum

Volumn 39, Issue 2, 1996, Pages 217-223

  Nassif, Anis ^a   Longo, Walter E ^a,b   Mazuski, John E ^a   Vernava, Anthony M ^a   Kaminski, Donald L ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Surgery ^*  (United States)

Author keywords

Cytokines; Inflammatory bowel disease; Platelet activating factor (PAF)

Indexed keywords

CYTOKINE; ICOSANOID; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ARTICLE; BLOOD VESSEL PERMEABILITY; ENTERITIS; HUMAN; LEUKOCYTE AGGREGATION; PATHOGENESIS; THROMBOCYTE AGGREGATION;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; PLATELET ACTIVATING FACTOR;

EID: 0030051862     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02068079     Document Type: Article

References (66)

1. Campbell CA, Walker-Smith JA, Hindocha P, Adinolfi M. Acute phase proteins in chronic inflammatory bowel disease in childhood. J Pediatr Gastroenterol Nutr 1982; 1:193-200.
2. Chambers RE, Stross P, Barry RE, Whicher JT. Serum amyloid A protein compared with C-reactive protein, alpha 1-antitrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest 1987;17:460-7.
3. Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis: serum C-reactive protein helps the most. J Clin Gastroenterol 1988;10:41-5.
4. Pinckard RN, Ludwig JC, McManus LM. Platelet-activating factors. In: Gallin JI, Goldstein IM, Synderman R, eds. Inflammation: Basic principles and clinical correlates. New York: Raven Press, 1988:139-67.
5. Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K. Cytokines in inflammatory bowel disease. Scand J Gastroenterol 1992;27:897-906.
6. Stadnyk AW. Cytokine production by epithelial cells. FASEB J 1994;8:1041-7.
7. Radema SA, Van Deventer SJ, Cerami A. Interleukin 1β is expressed predominantly by enterocytes in experimental colitis. Gastroenterology 1991;100:1180-6.
8. Jones SC, Trejdosiewicz LK, Banks RE, et al. Expression of interleukin-6 by intestinal enterocytes. J Clin Pathol 1993;46:1097-100.
9. Dinarello CA. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med 1984;311:1413-8.
10. Fey GH, Gauldie J. The acute phase response of the liver in inflammation. Prog Liver Dis 1990;9:89-116.
11. Filkins JP. Cytokines: mediators of the septic syndrome and septic shock. In: Taylor RW, Shoemaker WC, eds. Critical care: state of the art. Vol. 12. Fullerton, CA: Society of Critical Care Medicine, 1991:351-71.
12. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39-48.
13. Prescott SM, Zimmerman GA, McIntyre TM. Platelet-activating factor. J Biol Chem 1990;265:17381-4.
14. Benveniste J. Platelet activating factor, a new mediator of anaphylaxis from rabbit and human basophils. Nature 1974;249:581-4.
15. Chignard M, Le Couedic JP, Tence M, Vargaftig BB, Benveniste J. The role of PAF in platelet aggregation. Nature 1979;279:779-880.
16. Doebber JW, Wu MS, Shen TY. Platelet activating factor intravenous infusion in rat stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils. Biochem Biophys Res Commun 1984;125:980-7.
17. Humphrey DM, McManus LM, Satouchi K, Hanahan DJ, Pinckard RN. Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. Lab Invest 1982;46:422-7.
18. McManus LM, Hanahan DJ, Demopoulos CA, Pinckard RN. Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet activating factor (PAF), in the rabbit. J Immunol 1980;124:2919-24.
19. Poitevin B, Mencia-Huerta JM, Roubin R, Benveniste J. Role of PAF acether (platelet activating factor) in neutrophil activation. In: Said SI, ed. Pulmonary circulation and acute lung injury. New York: Furtura Publishing, 1985:357-73.
20. Camussi G, Brentjens J, Bussolino F, Tetta C. Role of platelet activating factor in immunopathological reactions. In: Otterness I, ed. Inflammation research. Vol. 11. New York: Raven Press, 1986:92-108.
21. Tagesson C, Lindahl M, Otamiri T. BN 52021 ameliorates mucosal damage associated with small intestinal ischemia in rats. In: Braquet P, ed. Ginkgolides: chemistry, biology, pharmacology and clinical science. Barcelona: Prous Science Publishers, 1988:553-61.
22. Wallace JL, Steel G, Whittle B, Lagente V, Vargaftig BB. Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Gastroenterology 1983;93:765-73.
23. Rosam AC, Wallace JL, Whittle B. Potent ulcerogenic actions of platelet- activating factor on the stomach. Nature 1986;319:54-6.
24. Wallace JL. Release of platelet-activating factor (PAP) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. Can J Physiol Pharmacol 1988;66:422-5.
25. Eliakim R, Karmeli F, Razin E, Rachmilewitz D. Role of platelet activating factor in ulcerative colitis. Gastroenterology 1988;95:1167-72.
26. Denizot Y, Chaussade S, Nathan N. PAF-acether and acetylhydrolase in stool of patients with Crohn's Disease. Dig Dis Sci 1992;37:432-7.
27. Rachmilewitz D, Eliakim R, Simon P, Ligumsky M, Karmeli F. Cytokines and platelet-activating factor in human inflamed colonie mucosa. Agents Actions 1992; Spec No:C32-6.
28. Sobhani I, Hochlaf S, Denizot Y, et al. Raised concentrations of platelet-activating factor in colonie mucosa of Crohn's disease patients. Gut 1992;33:1220-5.
29. Sharon P, Ligumsky D, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis: enhanced production during active disease and inhibition by sulphasalazine. Gastroenterology 1978;75:638-40.
30. Hawkey CJ, Truelove SC. Effect of prednisolone on prostaglandins synthesis by rectal mucosa in ulcerative colitis. Gut 1981;22:190-3.
31. Hawkey CJ, Truelove SC. Inhibition of prostaglandin synthetase in human rectal mucosa. Gut 24;1983:213-7.
32. Hawkey CJ, Karmeli F, Rachmilewitz D. Imbalance of prostacyclin and thromboxane synthesis in Crohn's Disease. Gut 1983;24:881-5.
33. Boughton-Smith NK, Hawkey CJ, Whittle B. Biosynthesis of lipoxygenase and cyclooxygenase products from (14C) arachidonic acid by human colonie mucosa. Gut 1983;24:1176-82.
34. Lobos EA, Sharon P, Stenson WF. Chemotactic activity in inflammatory bowel disease: role of leukotriene B4. Dig Dis Sci 1987;32:1380-8.
35. Olaison G, Sjodahl R, Tagesson C. Increased phospholipase A2 activity of ileal mucosa in Crohn's disease. Digestion 1988;41:136-41.
36. Olaison G, Sjodahl R, Tagesson C. Increase in permeability and phospholipase A2 activity of colonie mucosa in Crohn's colitis. Digestion 1989;43:228-33.
37. Donowitz M. Arachidonic acid metabolites and their role in inflammatory bowel disease: an update requiring addition of a pathway. Gastroenterology 1985;88: 580-7.
38. Braquet P, Vargaftig BB. Pharmacology of platelet activating factor. Transplant Proc 1986;28:10-9.
39. Tagesson C, Franzen L, Dahl G, Westrom B. Lysophosphatidylcholine increases rat ileal permeability to macromolecules. Gut 1985;26:369-77.
40. Rachmilewitz D, Simon PL, Schwartz LW, Griswold DE, Fondacaro JD, Wasserman MA. Inflammatory mediators of experimental colitis in rats. Gastroenterology 1989; 97:326-37.
41. Rachmilewitz D, Simon PL, Sjogrn R, Fondacaro JD, Wasserman MA, Bodecker E. Interleukin-1: a sensitive maker of colonie inflammation. Gastroenterology 1989; 94:A363.
42. Mahida YR, Jones PD, Daneshmend TK, Hawkey CJ. Peptide regulatory factors in the gut. Recent Adv Gastroenterology 1990;8:61-80.
43. Durum SK, Schmidt JA, Oppenheim JJ. Interleukin 1: an immunological perspective. Annu Rev Immunol 1985; 3:263-87.
44. Elner VM, Streiter RM, Elner SG, Baggiolini M, Lindley I, Kunkel SL. Neutrophil chemotactic factor (IL8) gene expression by cytokine-treated retinal pigment epithelial cells. Am J Pathol 1990;136:745-50.
45. Mahida YR, Lamming CE, Gallagher A, Hawthorne AB, Hawkey CJ. 5-Aminosalicylic acid is a potent inhibitor of ILlB production in organ culture of colonie biopsies form patients with inflammatory bowel disease. Gut 1991;32:50-4.
46. Izzo RS, Witkon K, Chen AI, Hadjiyane C, Weinstein M, Pellecchia C. Neutrophil-activating peptide (interleukin-8) in colonie mucosa from patients with Crohn's disease. Scand J Gastroenterol 1993;28:296-300.
47. Satsangi J, Wolstencroft RA, Cason J, Ainley CC, Dumonde CC, Thompson RP. Interleukin 1 in Crohn's disease. Clin Exp Immunol 1987;67:594-605.
48. Mazlam MZ, Hodgson HJ. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992;33:773-8.
49. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's Disease. Clin Exp Immunol 1993;94:174-81.
50. Mitsuyama K, Sasaki E, Toyonaga A, et al. Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion 1991;50:104-11.
51. Mazlam MZ, Hodgson HJ. Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut 1994;35: 77-83.
52. Raab Y, Hallgren R, Gerdin B. Enhanced intestinal synthesis of interleukin-6 is related to the disease severity and activity in ulcerative colitis. Digestion 1994;55:44-9.
53. Jones SC, Crabtree JE, Rembacken BJ, et al. Mucosal interleukin-6 secretion in ulcerative colitis: effects of anti-inflammatory drugs and T-cell stimulation. Scand J Gastroenterol 1994;29:722-8.
54. Sher ME, D'Angelo AJ, Stein TA, Bailey B, Burns G, Wise L. Cytokines in Crohn's colitis. Am J Surg 1995; 169:133-6.
55. Mahida YR, Ceska M, Effenberger F, Kurlak L, Lindley I, Hawkey CJ. Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis. Clin Sci 1992;82:273-5.
56. Izzo RS, Witkon K, Chen AI, Hadjiyane C, Weinstein MI, Pellecchia C. Interleukin-8 and neutrophil markers in colonie mucosa from patients with ulcerative colitis. Am J Gastroenterol 1992;87:1447-52.
57. Mitsuyama K, Toyonaga A, Sasaki E, et al. IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol 1994;96: 432-6.
58. Mazzucchelli L, Hauser C, Zgraggen K, et al. Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol 1994;144:997-1007.
59. Mahida YR, Kurlak L, Hawkey CJ. Circulating and tissue interleukin 2 receptor levels in inflammatory bowel disease. Clin Exp Immunol 1990;82:75-80.
60. Youngman KR, Simon PL, West GA, et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993;104:749-58.
61. McCabe RP, Secrist H, Botney M, Egan M, Peters MG. Cytokine mRNA expression in intestine from normal and inflammatory bowel disease patients. Clin Immunol Immunopathol 1993;66:52-8.
62. Gahring LC, Buckley A, Daynes RA. Presence of epidermal-derived thymocyte activating factor/interleukin 1 in normal human stratum corneum. J Clin Invest 1985;76: 1585-91.
63. Hauser C, Saurat JH, Schmitt A, Jaunin F, Dayer JM. Interleukin 1 is present in normal human epidermis. J Immunol 1986;136:3317-23.
64. Kirnbauer R, Köck A, Schwarz T, et al. IFN-β2, B-cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines. J Immunol 1989;142:1922-8.
65. Köck A, Schwarz T, Kirnbauer R, et al. Human keratinocytes are a source for tumor necrosis factor a: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med 1990;172: 1609-14.
66. Reinecker HC, Loh EY, Ringler DJ, Mehta A, Rombeau JL, MacDermott RP. Monocyte-chemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa. Gastroenterology 1995;108:40-50.